Skip to main content

Table 4 Univariate and multivariate analyses of preoperative prognostic factors for recurrence-free survival and overall survival

From: Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer

 Recurrence-free survivalOverall survival
 Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
 HR95% CIpHR95% CIpHR95% CIpHR95% CIp
Sex
 Male1.700.77–3.740.19   1.230.33–4.640.76   
 Female1     1     
Age (years)
  < 651     1     
  ≥ 650.950.42–2.180.91   1.460.39–5.490.58   
AV distance (cm)
  < 51.290.64–2.580.48   1.690.45–6.390.44   
  ≥ 51     1     
CEA level (ng/mL)
  < 51     1     
  ≥ 51.800.93–3.530.84   1.160.34–3.970.81   
cT stage
 T2 and T31  1  1     
 T43.001.53–5.910.0012.010.92–4.420.083.240.99–10.620.05   
cN stage
 Negative1     1     
 Positive1.350.69–2.620.38   0.870.27–2.850.82   
Clinical LPLN metastasis
 Negative1     1     
 Positive1.710.84–3.480.14   1.380.37–5.210.64   
Clinical CRM            
 Negative1  1  1  1  
 Positive2.991.54–5.800.0011.970.90–4.350.094.431.30–15.140.023.240.90–11.680.07
ymrEMVI
 Negative1  1  1  1  
 Positive3.371.72–6.61< 0.0012.741.36–5.500.0054.431.35–14.510.013.150.91–10.890.07
TVRR (%)
  < 603.371.53–7.420.0033.481.57–7.720.0023.900.84–18.060.08   
  ≥ 601  1  1     
  1. HR hazard ratio, CI confidence interval, AV anal verge, CEA carcinoembryonic antigen, LPLN lateral pelvic lymph node, CRM circumferential resection margin; ymrEMVI extramural venous invasion based on magnetic resonance imaging after neoadjuvant chemotherapy, TVRR tumor volume reduction rate